Lecture 12: Thrombosis in Cancer

Gerald A Soff, MD

Presentation Date:

November 21, 2024

> Venous thromboembolism (VTE), is major source of morbidity and mortality in cancer patients.

> Incidence rates of cancer-associated thrombosis (CAT) vary with cancer type, stage, treatment, and comorbidities, but it is estimated that approximately 15-20 % of cancer patients will develop a venous thromboembolic episode at some point during the course of their illness.

Gerald A Soff MD
Chief, General Hematology Service
University of Miami Health System/Sylvester Comprehensive Cancer Center
Email: gas199@miami.edu

Disclosures:
> Research Support (Past 2 years): Amgen, Sobi Pharmaceuticals, Anthos Therapeutics, Alpine Immune Sciences (Data Safety Monitoring Committee)
> Advisory Boards (Past 2 years): Sobi Pharmaceuticals, Sanofi, Agios Pharmaceuticals.

Hanny Al-Samkari, M.D.
Hematology Oncology Division
Massachusetts General Hospital
hal-samkari@mgh.Harvard.edu

Research Support: Agios, Sobi, Amgen, Alpine Immune Sciences (Data Safety Monitoring Committee), Novartis, Vaderis

Consultancy: Agios, Sobi, Argenx, Novartis, Alnylam, Sanofi, Amgen, Pharmacosmos

Left: Armand Trousseau
(14 October 1801 – 23 June 1867)

Starting in 2025, lectures are eligible for Continuing Education Credit.
Link for CE:

Link For Continuing Education Credit

Slide Deck